Abstract
The use of ziconotide in intrathecal analgesia (ITA) has been limited by dose-related side effects. We present our experience with ziconotide as first-line intrathecal monotherapy in patients with chronic pain and present our low and slow dosing algorithm aimed at reducing side effects and appropriately managing pain in these patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
